Organization · Venture Capital
JLS Fund
JLS Fund is a New York-based venture capital fund specializing in neuromedicine, focusing on psychedelic-inspired therapeutics and neuropsychiatric disorders. They invest in early-stage companies developing innovative treatments and enabling technologies.
Overview
What JLS Fund does
What JLS Fund is
JLS Fund is a New York-based venture capital fund specializing in neuromedicine, focusing on psychedelic-inspired therapeutics and neuropsychiatric disorders. They invest in early-stage companies developing innovative treatments and enabling technologies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 24, 2026
Official channels
Find JLS Fund elsewhere
Open the official website or a supported primary organization account.
Capability profile
JLS Fund as a funder
Investment thesis
JLS Fund backs early-stage neuromedicine companies, focusing on psychedelic-derived and inspired therapies along with the necessary infrastructure for their delivery, aiming for both financial returns and leadership in a rapidly evolving sector.
Focus narrative
JLS Fund invests in neuromedicine, with a focus on pre-seed, seed, Series A, and later-stage secondaries transitioning to buyout. The fund's investment thesis includes companies that address urgent unmet needs in the treatment of neuropsychiatric disorders, particularly through innovative psychedelic therapies.
Value beyond capital
JLS Fund provides strategic support to its portfolio companies, leveraging deep industry knowledge and connections in the psychedelic and neuromedicine sectors. The team’s extensive experience in psychedelic research and philanthropy enhances their ability to guide companies through regulatory challenges and market entry.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Growth Equity
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 30
- Recorded notable exits
- MindMed, Cybin, and atai Life Sciences
Portfolio context
Notable portfolio companies include: Enthea - a mental health company providing access to safe and affordable psychedelic-assisted therapy; ProNovo - developing precision treatments for neuropsychiatric disorders; Psilera Bioscience - focusing on psychoactive natural products for neurological applications; Tripp - a wellness platform recognized for its innovative approach; Immunis Biomedical - developing biologics for age-related diseases; Gilgamesh - aiming to transform psychiatric disease treatment.
Common questions
What to know about JLS Fund
Upseed classifies JLS Fund under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 24, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.